Jinxi Lin1, Hongwei Zheng1, Brett L Cucchiara1, Jiejie Li1, Xingquan Zhao1, Xianhong Liang1, Chunxue Wang1, Hao Li1, Michael T Mullen1, S Claiborne Johnston1, Yilong Wang2, Yongjun Wang2. 1. From the Department of Neurology (J. Lin, H.Z., J. Li, X.Z., X.L., C.W., H.L., Yilong Wang, Yongjun Wang), Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases (J. Lin, J. Li, X.Z., X.L., C.W., H.L., Yilong Wang, Yongjun Wang); Center of Stroke (J. Lin, H.Z., J. Li, X.Z., X.L., C.W., H.L., Yilong Wang, Yongjun Wang), Beijing Institute for Brain Disorders; Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease (J. Lin, J. Li, X.Z., X.L., C.W., H.L., Yilong Wang, Yongjun Wang), China; Department of Neurology (B.L.C., M.T.M.), University of Pennsylvania, Philadelphia; and Dell Medical School (S.C.J.), University of Texas-Austin, TX. 2. From the Department of Neurology (J. Lin, H.Z., J. Li, X.Z., X.L., C.W., H.L., Yilong Wang, Yongjun Wang), Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases (J. Lin, J. Li, X.Z., X.L., C.W., H.L., Yilong Wang, Yongjun Wang); Center of Stroke (J. Lin, H.Z., J. Li, X.Z., X.L., C.W., H.L., Yilong Wang, Yongjun Wang), Beijing Institute for Brain Disorders; Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease (J. Lin, J. Li, X.Z., X.L., C.W., H.L., Yilong Wang, Yongjun Wang), China; Department of Neurology (B.L.C., M.T.M.), University of Pennsylvania, Philadelphia; and Dell Medical School (S.C.J.), University of Texas-Austin, TX. yongjunwang1962@gmail.com yilong528@gmail.com.
Abstract
OBJECTIVE: To determine the association of lipoprotein-associated phospholipase A2 (Lp-PLA2) measured in the acute period and the short-term risk of recurrent vascular events in patients with TIA or minor stroke. METHODS: We measured Lp-PLA2 activity (Lp-PLA2-A) in a subset of 3,201 participants enrolled in theCHANCE (Clopidogrelin High-Risk Patients with Acute Non-disabling Cerebrovascular Events) trial. Participants with TIA or minor stroke were enrolled within 24 hours of symptom onset and randomized to single ordual antiplatelet therapy. In the current analysis, the primary outcome was defined as the composite of ischemic stroke, myocardial infarction, or death within 90 days. RESULTS: The composite endpoint occurred in 299 of 3,021 participants (9.9%). The population average Lp-PLA2-A level was 209 ± 59 nmol/min/mL (95% confidence interval [CI] 207-211). Older age, male sex, and current smoking were associated with higher Lp-PLA2-A levels. Lp-PLA2-A was significantly associated with the primary endpoint (adjusted hazard ratio 1.07, 95% CI 1.01-1.13 for every 30 nmol/min/mL increase). Similar results were seen for ischemic stroke alone. Adjustment for low-density lipoprotein cholesterol attenuated the association between Lp-PLA2-A and the primary endpoint (adjusted hazard ratio 1.04, 95% CI 0.97-1.11 for every 30 nmol/min/mL increase). CONCLUSIONS: Higher levels of Lp-PLA2-A in the acute period are associated with increased short-term risk of recurrent vascular events.
RCT Entities:
OBJECTIVE: To determine the association of lipoprotein-associated phospholipase A2 (Lp-PLA2) measured in the acute period and the short-term risk of recurrent vascular events in patients with TIA or minor stroke. METHODS: We measured Lp-PLA2 activity (Lp-PLA2-A) in a subset of 3,201 participants enrolled in the CHANCE (Clopidogrel in High-Risk Patients with Acute Non-disabling Cerebrovascular Events) trial. Participants with TIA or minor stroke were enrolled within 24 hours of symptom onset and randomized to single or dual antiplatelet therapy. In the current analysis, the primary outcome was defined as the composite of ischemic stroke, myocardial infarction, or death within 90 days. RESULTS: The composite endpoint occurred in 299 of 3,021 participants (9.9%). The population average Lp-PLA2-A level was 209 ± 59 nmol/min/mL (95% confidence interval [CI] 207-211). Older age, male sex, and current smoking were associated with higher Lp-PLA2-A levels. Lp-PLA2-A was significantly associated with the primary endpoint (adjusted hazard ratio 1.07, 95% CI 1.01-1.13 for every 30 nmol/min/mL increase). Similar results were seen for ischemic stroke alone. Adjustment for low-density lipoprotein cholesterol attenuated the association between Lp-PLA2-A and the primary endpoint (adjusted hazard ratio 1.04, 95% CI 0.97-1.11 for every 30 nmol/min/mL increase). CONCLUSIONS: Higher levels of Lp-PLA2-A in the acute period are associated with increased short-term risk of recurrent vascular events.
Authors: Robert L Wilensky; Yi Shi; Emile R Mohler; Damir Hamamdzic; Mark E Burgert; Jun Li; Anthony Postle; Robert S Fenning; James G Bollinger; Bryan E Hoffman; Daniel J Pelchovitz; Jisheng Yang; Rosanna C Mirabile; Christine L Webb; LeFeng Zhang; Ping Zhang; Michael H Gelb; Max C Walker; Andrew Zalewski; Colin H Macphee Journal: Nat Med Date: 2008-09-21 Impact factor: 53.440
Authors: Hok-Hay S Oei; Irene M van der Meer; Albert Hofman; Peter J Koudstaal; Theo Stijnen; Monique M B Breteler; Jacqueline C M Witteman Journal: Circulation Date: 2005-02-08 Impact factor: 29.690
Authors: Michelle O'Donoghue; David A Morrow; Marc S Sabatine; Sabina A Murphy; Carolyn H McCabe; Christopher P Cannon; Eugene Braunwald Journal: Circulation Date: 2006-03-14 Impact factor: 29.690
Authors: Michelle L O'Donoghue; Eugene Braunwald; Harvey D White; Dylan P Steen; Mary Ann Lukas; Elizabeth Tarka; P Gabriel Steg; Judith S Hochman; Christoph Bode; Aldo P Maggioni; KyungAh Im; Jennifer B Shannon; Richard Y Davies; Sabina A Murphy; Sharon E Crugnale; Stephen D Wiviott; Marc P Bonaca; David F Watson; W Douglas Weaver; Patrick W Serruys; Christopher P Cannon; Dylan L Steen Journal: JAMA Date: 2014-09-10 Impact factor: 56.272
Authors: Mitchell S V Elkind; Wanling Tai; Kristen Coates; Myunghee C Paik; Ralph L Sacco Journal: Cerebrovasc Dis Date: 2008-11-15 Impact factor: 2.762
Authors: Brett L Cucchiara; Steve R Messe; Lauren Sansing; Larami MacKenzie; Robert A Taylor; James Pacelli; Qaisar Shah; Scott E Kasner Journal: Stroke Date: 2009-05-21 Impact factor: 7.914
Authors: Mandip S Dhamoon; Ying-Kuen Cheung; Yeseon P Moon; Clinton B Wright; Ralph L Sacco; Mitchell S V Elkind Journal: PLoS One Date: 2019-04-01 Impact factor: 3.240